Compare Hims and Hers Health Inc (HIMS) vs Iris Energy Limited (IREN) Price & Performance

HIMS stock trades at $28.06, down 5.01% on the day, reflecting bearish technical signals and negative earnings surprises in recent quarters. The company reported strong revenue growth to $2.35 billion in 2025 but swung to a net loss of -$142 million in 2026, with profitability metrics deteriorating. Multiple securities class action lawsuits filed in October 2026 create significant legal overhangs, while analyst consensus remains cautiously optimistic with a $32.17 price target despite mixed fundamental performance.

The outlook is clouded by legal risks and profitability challenges, though the 15% upside to consensus target suggests potential recovery if execution improves. Key risks include ongoing litigation outcomes and the company's ability to return to sustainable profitability amid competitive pressures in the telehealth sector.

IREN is trading at $35.71, down 7.7% over 24 hours, reflecting ongoing investor concerns despite strong analyst support. The stock shows bearish technical signals with negative earnings trends, having missed EPS expectations for three consecutive quarters. However, the company maintains robust revenue growth projections and secured significant contracts including a $9.7 billion Microsoft deal, positioning it for potential long-term AI infrastructure growth.

While IREN faces execution risks with negative profit margins and high valuation multiples, Wall Street remains overwhelmingly bullish with an $81 consensus price target representing 127% upside. The key investment thesis hinges on successful execution of AI infrastructure expansion, but investors must weigh substantial capital expenditure requirements against the company's ambitious revenue growth projections through 2030.